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Targeted therapies are effective in subsets of lung cancers with EGFR mutations 
and ALK translocations. Large-scale genomics have recently expanded the lung 
cancer landscape with FGFR1 amplification found in roughly 20% of squamous cell 
carcinomas (SCCs). However, the response rates have been low for biomarker-
directed FGFR inhibitor therapy in SCC, which contrasts to the relatively high 
rates of response seen in EGFR mutant and ALK translocated lung cancers treated 
with EGFR inhibitors and ALK inhibitors, respectively. In order to better 
understand the low response rates of FGFR1-amplified lung cancers to FGFR 
inhibitors, relationships between gene copy number, mRNA expression, and protein 
expression of FGFR1 were assessed in cell lines, tumor specimens, and data from 
The Cancer Genome Atlas (TCGA). The importance of these factors for the 
sensitivity to FGFR inhibitors was determined by analyzing drug screen data and 
conducting in vitro and in vivo experiments. We report that there was a 
discrepancy between FGFR1 amplification level and FGFR1 protein expression in a 
number of these cell lines, and the cancers with unexpectedly low FGFR1 
expression were uniformly resistant to the different FGFR inhibitors. Further 
5 
 
interrogation of the receptor tyrosine kinase activity in these discordant cell lines 
revealed co-activation of HER2 and PDGFRα caused by gene amplification or 
ligand overexpression maintained PI3K and MEK/ERK signaling even in the 
presence of FGFR inhibitor. Accordingly, co-inhibition of FGFR1 and HER2 or 
PDGFRα led to enhanced drug responses. In contrast, FGFR1-amplified high 
FGFR1 protein expressing lung cancers are sensitive to FGFR inhibitor 
monotherapy by downregulating ERK signaling. Addition of a PI3K inhibitor to 
these high FGFR1 protein expressing cancers further sensitized them to FGFR 
inhibitor. These data reveal that biomarker-directed trials for FGFR1-amplified 
SCC require assessment of FGFR1 protein expression and uncover novel 
therapeutic strategies for FGFR1-amplified SCC with low FGFR1 protein 
expression. 
 





Lung cancer is the leading cause of cancer-related death in the world. Histologically, 
lung cancer can be grouped as small cell-lung cancer and non-small cell lung cancer 
(NSCLC). NSCLC consists of adenocarcinoma, squamous cell carcinoma (SCC), and 
large cell carcinoma. Traditionally, NSCLC has been treated with platinum-based 
doublet chemotherapeutic agents, however, the identification of driver oncogenes in 
many of these cancers have changed the way adenocarcinomas are treated. Currently, 
molecularly targeted therapies targeting somatically activated oncogenes such as 
mutant EGFR or translocated ALK, RET, or ROS1 are part of clinical treatment 
plans 1-3. In contrast to the significant advances in the treatment for adenocarcinoma, 
there have been no targeted therapies implemented for SCC 4.  
 The fibroblast growth factor receptor (FGFR) signaling plays crucial roles in 
regulating tumor cell proliferation, angiogenesis, migration, and survival 5-7. 
Deregulation of FGFR signaling has been reported due to genetic modification or 
overexpression of receptors in many types of cancers such as breast and bladder 6. 
In lung cancer, FGFR1 gene amplification is found in 10 to 20% of SCC samples and 
thought to be the commonest driver alteration in lung SCC 8-15. While most of studies 
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evaluated FGFR1 copy number by FISH analysis, the frequency defined by next 
generation sequencing were 7 and 9%, which were lower than FISH analysis 16, 17. 
Accordingly, a few clinical trials targeting patients with histologically/cytologically 
confirmed advanced solid tumors with FGFR1 or FGFR2 amplification or FGFR3 
mutation are underway. In a phase I study, 21 patients with FGFR1-amplified lung 
SCC were treated with the pan-FGFR inhibitor NVP-BGJ398 at the maximum 
tolerated dose. Tumors from four of these patients achieved partial regression 18. 
Another pan-FGFR inhibitor, AZD4547, achieved one partial response among 14 
patients with FGFR1 amplified stage IV lung SCC, but failed to meet the primary 
efficacy endpoint for continuation 19. These initial clinical results suggest some 
FGFR1-amplified lung SCC are sensitive to FGFR inhibitors, however, the response 
rate is lower compared to other molecularly targeted drugs. Therefore, there is a 
clear need to better define the patient population that would benefit from FGFR 
inhibitors. 
  
Consistent with the low rate of response in the clinic, we report four of six FGFR1-
amplified lung cancer cells are insensitive to FGFR inhibitors. While these cell lines 
were all confirmed to harbor FGFR1 gene amplification, we surprisingly found the 
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expression levels of mRNA and protein were widely variable. Furthermore, the lung 
cancers with high FGFR1 protein were sensitive to FGFR inhibitors, however, the 
FGFR1 amplified lung cancers with low FGFR1 protein invariably had a co-active 
receptor tyrosine kinase (RTK) rendering these cancers insensitive to FGFR 
inhibitors. We found co-inhibition of FGFR1 and the active RTK is required to 
downregulate downstream signaling and achieve growth suppression. These results 
suggest FGFR inhibitors can be effective as monotherapy in FGFR1-amplified lung 
cancers with high FGFR1 expression; however, assaying for FGFR1 protein 
expression in FGFR1-amplified cancers is essential. In the low FGFR1 protein 
expressing lung cancers, there exists co-driver RTKs, in which targeting with 





Lung cancer cells harboring FGFR1 amplification shows variable sensitivity to 
FGFR1 inhibitors. 
 
Amplification of oncogenic RTKs often predicts sensitivity to the corresponding RTK 
inhibitor; for instance, HER2 amplification as determined by FISH predicts 
sensitivity to HER2 inhibitors in breast cancer 20. We therefore sought to determine 
whether FGFR1-amplified lung cancer cells predicted sensitivity to FGFR inhibitor. 
First, we have chosen seven cell lines based on previous reports that they possessed 
FGFR1 amplification 8, 9. Characteristics of each cell line are shown in 
Supplementary Table 1. Results of gene copy number analysis by quantitative PCR 
and FISH are shown in Figure 1a, 1b, Supplementary Figure S1, and Supplementary 
Table 2. We excluded NCI-H2444 cells for further analysis because the cells showed 
extra copies of FGFR1 as a result of polysomy of chromosome 8 (Supplementary 
Figure S1). Next, we determined the sensitivity of FGFR1 amplified lung cancer cell 
lines (NCI-H1581, DMS-114, NCI-H520, NCI-H1703, HCC95, and Calu-3) to three 
FGFR inhibitors: NVP-BGJ398, PD-173074, and AZD4547. As shown in Figure 1c, 
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only two of these cell lines, NCI-H1581 and DMS-114, were found to be sensitive to 
NVP-BGJ398. We found the data to be consistent for PD-173074 and AZD4547 as 
well (Figure 1d and 1e). While NCI-H520 cells showed intermediate sensitivity to 
the FGFR inhibitors, the NCI-H1703, HCC95, and Calu-3 cells were insensitive. 
These results show that FGFR1 amplification status alone is not correlated with 
sensitivity to FGFR1 inhibitors. 
 
Protein expression of FGFR1 is not predicted simply by gene copy number. 
 
We next determined whether the FGFR1 gene is translated and transcribed in these 
cells. Interestingly, FGFR1 mRNA and protein expression were not always 
upregulated in the presence of gene amplification (Figure 1f and 1g). Therefore, no 
relationship was observed between protein expression and gene copy number defined 
by FISH (Supplementary Figure S2a) or quantitative PCR (Supplementary Figure 
S2b). In contrast, mRNA and protein expression was well correlated except for in the 
NCI-H1703 cell line (Supplementary Figure S2c). Importantly, none of the FGFR1-
amplified, but low FGFR1 protein expressing cell lines, were sensitive to FGFR 
inhibitors among NCI-H1703, HCC95, and Calu-3 (Figure 1g and Supplementary 
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Figure S2d). We determined CpG island methylation in the FGFR1 promoter, and 
found there was an absence of methylation in the HCC95 and Calu-3 cells 
(Supplementary Figure S3). 
 
Both protein expression and gene amplification of FGFR1 are required to show 
sensitivity to FGFR inhibitor. 
 
To determine whether high FGFR1 mRNA expression is sufficient enough to predict 
sensitivity to FGFR inhibitors, we evaluated the effect of PD-173074 on cell 
proliferation in a large panel of lung cancer cell lines (Figure 2a). Among cell lines 
with higher expression of FGFR1, two of 5 FGFR1 amplified cells were sensitive to 
PD-173074, whereas none of the 38 cell lines without FGFR1 amplification showed 
sensitivity to the FGFR inhibitor (p < 0.05 by fisher’s exact test) (Figure 2b). 
Furthermore, the two cell lines that were sensitive not only had high FGFR1 mRNA 
expression, but had high FGFR1 protein expression. These results indicate that 
mRNA expression is not the sole factor to predict sensitivity and suggest that only 
FGFR1-amplified lung cancers with expected high corresponding FGFR1 protein 
expression are sensitive to FGFR inhibitors. In agreement with this, the Colo-699N 
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non-FGFR1-amplified cells are insensitive to NVP-BGJ398 even though the cells 
express comparable level of FGFR1 protein to NCI-H1581 cells (Figure 2c and 2d 
and Supplementary Figure S4). To further determine the efficacy of FGFR inhibitor 
in vivo, NCI-H1581 and Colo-699N were xenografted and treated with NVP-BGJ398. 
The data demonstrate, consistent with the in vitro data, in vivo sensitivity of 
xenografted NCI-H1581 tumors to NVP-BGJ398 (Figure 2e). In contrast, NVP-
BGJ398 had no effect on the growth of Colo-699N tumors (Figure 2f). These data 
demonstrate that both amplification of FGFR1 and high protein expression in a 
tumor are necessary for sensitivity to FGFR inhibitors.  
 
FGFR inhibitor suppresses MEK/ERK signaling in FGFR-inhibitor sensitive cell 
lines. 
 
We next investigated downstream signaling regulated by FGFR1 in FGFR1-
amplified lung cancer cell lines. Since suppression of both the PI3K/AKT and 
MEK/ERK signaling underlies many of the antitumor effects induced by TKIs in 
RTK-addicted tumors, which converge on the mTORC1 pathway 21, 22, these signaling 
pathways were investigated. We found the FGFR1-amplified lung cancer cell lines 
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had variable levels of FGFR1 phosphorylation and protein levels (Figure 3a). 
Interestingly, FGFR inhibitor treatment downregulated phosphorylation of ERK as 
well as S6, a readout for mTORC1 activity 23, in FGFR inhibitor-sensitive and 
intermediately sensitive cell lines. However, the drug has no effect on ERK and S6 
phosphorylation in resistant cells (Figure 3b). Of note, AKT phosphorylation was not 
affected by FGFR inhibitor in either the sensitive or resistant group. Reduction of 
FGFR1 mRNA and protein by transfection of FGFR1-specific short-interfering 
siRNA recapitulated the inhibition of pERK following FGFR inhibitor (Figure 3c). 
These results demonstrate that FGFR1 mainly regulates MAPK signaling in FGFR 
inhibitor sensitive cell lines. Consistent with this, the extent of ERK suppression is 
associated with the degree of growth inhibition induced by FGFR inhibitor. NVP-
BGJ398 suppressed ERK phosphorylation in a dose-dependent manner that is 
associated with growth suppression induced by the drug (Figure 3d to 3f). 
Interestingly, the most sensitive cell line, NCI-H1581, has no measurable AKT 
phosphorylation (Figure 3a), raising the possibility that PI3 kinase inhibition may 
further sensitize the FGFR1-amplified and high FGFR1 protein DMS-114 and NCI-
H520 cell lines. Indeed, the combination of a PI3 kinase inhibitor GDC-0941 and 
NVP-BGJ398 led to complete suppression of S6 phosphorylation (Figure 3g) and 
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enhanced growth suppression compared to either drug alone (Figure 3h). These data 
indicate that in FGFR1- amplified lung cancer cell lines with high FGFR1 protein 
expression, FGFR inhibitors block pERK and TORC1 signaling, and the addition of 
a PI3K inhibitor further sensitizes these cancers through greater suppression of the 
PI3K/TORC1 pathway. However, in FGFR1-amplified lung cancer cells with low 
FGFR1 expression, pERK and TORC signaling are unaffected by FGFR inhibition. 
 
Additional driver oncogene activation mitigates the effect of FGFR1 inhibition in low 
FGFR1 protein expressing cells. 
 
To elucidate the mechanism of primary resistance to FGFR inhibitors in FGFR1 
amplified lung cancers, phosphorylation status of RTKs were examined in the 
insensitive cell lines. In the NCI-H1703 cell line, we identified high PDGFRα 
phosphorylation, consistent with reported amplification of PDGFRα in this cell line 
24, 25 (Figure 4a). In the Calu-3 cell line, we identified high phosphorylation of EGFR 
family proteins and MET on activation loop residues (Figure 4b). This cell line has 
reported HER2 amplification 26. In the HCC95 cell lines, an RTK array showed a 
similar pattern of EGFR family protein activation as the Calu-3 cell line (Figure 5a). 
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However, the cells did not have an EGFR mutation (Supplementary Table 1) or 
HER2 amplification (Figure 5b). Activation of EGFR family receptors can occur via 
ligand binding, resulting in hetero- and homo-dimerization with other EGFR family 
proteins. Recent findings showed that overexpression of neuregulin-1 (NRG1) can 
also drive HER3 activation by an autocrine signaling loop in a subset of non-HER2 
amplified cancers 27. Indeed, we found that HCC95 cells express high amounts of 
NRG1 mRNA and protein compared to other FGFR1-amplified cells (Figure 5c and 
d). Consistently, knockdown of NRG1 inhibited cell viability in HCC95 cells, while it 
had no effect on NCI-H520 cells (Figure 5e and 5f). Furthermore, addition of serum 
free media conditioned from the HCC95 cells activated HER3 protein and 
downstream AKT signaling in NCI-H1581 cells expressing low NRG1 (Figure 5g). 
These results demonstrate that autocrine production of NRG1 maintains the 
survival of HCC95 cells following FGFR inhibitor treatment.  
 
We next sought to determine whether addition of the appropriate TKI sensitized the 
NCI-H1703, HCC95 and Calu-3 cell line to FGFR inhibitor. Importantly, the addition 
of NVP-BGJ398 to an inhibitor targeting the co-activated RTK enhanced inhibition 
of cell growth in each FGFR1-amplified lung cancer with low FGFR1 protein 
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expression in five day growth assays (Figure 6a). Furthermore, combination of the 
FGFR inhibitor with the RTK inhibitor achieved better suppression of S6 
phosphorylation and expression of the mTORC1-sensitive anti-apoptotic protein 
MCL-1 28, resulting in enhanced apoptosis induction in these cells (Figure 6b). 
Intriguingly, phosphorylation of the FRS2, adaptor protein which mediate signaling 
from FGFR1 to effector proteins was not suppressed by either FGFR inhibitor or the 
single-agent RTK inhibitor, but was achieved by the combination of the drugs. These 
data implicate the interaction of FGFR1 and HER2 in the HCC95 and Calu-3 cells, 
and PDGFRα in the H1703 cells. Collectively, these data demonstrate that co-
activation of other RTKs mitigates the effect of FGFR inhibitor in FGFR1 amplified 
lung cancer with low FGFR1 protein expression. Consequentially, the combination 
of FGFR inhibitors with either Lapatinib or Imatinib is effective.  
 
Existence of co-activated RTKs in low FGFR1 expression in patients with FGFR1 
amplified lung SCC 
 
To further expand our findings, we have investigated FGFR1 protein expression in 
25 patient with FGFR1 gene amplified lung SCC identified by FISH analysis (Figure 
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7a). IHC stain identified only six of 25 tumors were positive for FGFR1 protein 
expression; only one case exhibited diffuse and strong expression. Furthermore, 
FGFR1 was not expressed in two cases harboring both FGFR1 and PDGFRα gene 
amplification. To validate the discrepancy between protein expression and gene 
amplification of FGFR1 using an independent data set, we analyzed an RNA SEQ 
data set of 178 lung SCCs from The Cancer Genome Atlas (TCGA) project. The 
analysis revealed that only eight samples show FGFR1 amplification with 
concomitant high mRNA expression among 30 FGFR1-amplified cancers (Figure 7b). 
Interestingly, overexpression of NRG1 is mutually exclusive to HER2 and PDGFRα 
amplification among FGFR1-amplified cancers (Figure 7b). Furthermore, tumors 
with gene amplification and mRNA expression do not have any co-existing driver 
oncogenes (Figure 7b). Collectively, these data are consistent with our findings in 
this study that FGFR1 amplified lung cancers with low FGFR1 protein depend on 
other RTKs for their growth, while FGFR1-amplified cancers with high FGFR1 






We have demonstrated that only some FGFR1 amplified lung cancer cell lines are 
sensitive to FGFR inhibitors. We further demonstrate that the cases which have 
amplified FGFR1 and insensitive have discordant levels of protein. These cancers 
with unexpectedly low levels of FGFR1 protein do not have MEK/ERK signaling 
under the control of FGFR1; instead, other co-active RTKs co-regulate this pathway. 
Therefore, FGFR inhibitors show efficacy only in the subset of FGFR1-amplified lung 
cancers that have high protein expression and activate the MEK/ERK pathway.  
 
The relationship between gene copy number and protein expression in FGFR1-
amplified cancers has been studied using tumor samples 12, 13, 15, 29. Kohler and 
colleagues studied copy number and protein expression levels of FGFR1 in 133 lung 
SCCs using FISH and IHC 12. While increased FGFR1 protein expression levels 
correlated with gene copy number as a whole, they also pointed out discordant cases 
exist in their cohort. Similarly, Kim et al. analyzed 262 patients with lung SCC and 
showed association between FGFR1 gene amplification and mRNA expression, 
however, about half of the cases expressed less than 1.5 fold of FGFR1 mRNA 
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compared to the housekeeping gene 13. Intriguingly, a patient derived tumor 
xenograft harboring FGFR1 amplification but discordant, low-level protein was less 
sensitive to AZD4547 compared to four other models harboring FGFR1 amplification 
with consistently high-level FGFR1 protein expression 30. Loss of FGFR1 protein 
expression in the presence of gene amplification could be mediated by aberrant DNA 
promoter methylation, a common feature of many human cancers 31, 32 . Whereas a 
large CpG island is observed in the promoter region of FGFR1 gene defined by UCSC 
genome browser, no methylation was observed in HCC95 and Calu-3 cells 
(Supplementary Figure S3). Other mechanisms including aberrant expression of 
microRNAs need to be considered in future studies. These results support the idea 
that both gene amplification and protein expression are needed for patient selection. 
The importance of FGFR1 protein expression in FGFR inhibitor sensitivity was also 
shown in a recent study by Wynes et al 29; However, they proposed that FGFR1 
mRNA and protein expression are the predictors of FGFR inhibitor Ponatinib 
regardless of gene amplification across all lung cancer histologies. In 
adenocarcinoma, some cells express FGFR1 protein without gene amplification, 
however, drug screening with the FGFR inhibitor PD-173074 indicates that none of 
the 51 lung adenocarcinoma cell lines tested were sensitive to PD-173074 (Figure 2a 
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and 2b). Furthermore, only NCI-H1581 and DMS-114 cells are sensitive to PD-
173074 and NVP-BGJ398 among 14 cell lines identified to be sensitive to Ponatinib 
in the study (Supplementary Table 3). These results suggest FGFR1-gene 
amplification is important to predict sensitivity against FGFR inhibitors, and the 
apparent discrepancy may be a result of drug promiscuity; in contrast to NVP-
BGJ398 and AZD4547 which are relatively selective pan-FGFR inhibitors 33, 34, 
Ponatinib inhibits a number of non-FGFR kinases with IC50 concentrations less than 
10nM, including VEGFR, PDGFR, EPH receptors, SRC, KIT, and RET 35.  
 
In this study, we found that FGFR1-amplified lung cancer cells that showed 
resistance to FGFR inhibitors had additional RTKs that activated survival signaling. 
We demonstrated Calu-3 HER2-amplified and NCI-H1703 PDGFRα-amplified cells 
are insensitive to NVP-BGJ398 and co-inhibition of HER2 and PDGFRα, respectively, 
lead to potent growth suppression. In addition, we found the HCC95 cell line 
possessed overexpression of NRG1, leading to activation of HER3. Co-inhibition with 
lapatinib sensitized these cells to FGFR inhibitor. Previous studies have also shown 
cross talk between FGFR and ERBB pathway in multiple tumor types 36-38. In lung 
cancer, activation of FGFR pathway is a cause of acquired resistance to EGFR 
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inhibitors in EGFR mutant cancer cell lines 36. Also, a switch from dependency on 
FGFR3 to ERBB family members were observed in FGFR inhibitor resistant FGFR3 
amplified or translocated lung cancers 38. Interestingly, we have demonstrated that 
tumors harboring both FGFR1 and PDGFRα amplification did not express FGFR1 
protein in our tissue microarray analysis. Furthermore, analysis of 178 lung SCC 
tumors from TCGA identified overexpression of NRG1 as mutually exclusive to 
HER2 and PDGFRα amplification. Notably, none of these alterations were identified 
in high mRNA expressing FGFR1 amplified tumors, consistent with our in vitro 
findings. Importantly, tumors with FGFR1 gene amplification that have concomitant 
high FGFR1 mRNA expression or positive FGFR1 IHC staining consist of only a 
subset of FGFR1 amplified tumors. These data are consistent with our in vitro 
findings, raising the possibility that stratification by combining FISH with protein 
expression analysis, such as immunohistochemistry, would inform which patients 
would be expected to respond. Furthermore, a search for other co-driver RTKs 
through sequencing and HER2 FISH analysis may identify patients whom would 
respond to FGFR-based combination therapies.  
 
While HER2 amplification is defined as an HER2/chromosome 17 centromere ratio 
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of more than 2.2, which correlates well with the response to anti-HER2 antibody in 
breast and gastric cancer, the definition of FGFR1 amplification has not been 
established yet 10, 11, 13, 14, 30, 39, 40. We observed no association between amplification 
level of FGFR1 and sensitivity to FGFR inhibitors in our cell line panel. In a phase 
I trial of AZD4547, although patients with FGFR1:CEP8 ratios of more than 2.8 
appeared to have better growth suppression in comparison to patients with 
FGFR1:CEP8 ratios between 2 to 2.8, the difference was not statistically significant 
and only one of seven patients with high FGFR1 amplified tumor achieved a partial 
response 19. The FGFR1 locus is heterogeneous, therefore the limitation of the 
resolution of FISH analysis may lead to false-positive detection of FGFR1 
amplification and might result in the lack of association with efficacy to FGFR 
inhibitor 4, 41. We also observed that gene copy number analysis by quantitative PCR 
did not correlate with FISH results because of aneuploidy. As FGFR1 copy number 
is determined by quantitative PCR and used as a selection criterion in current NVP-
BGJ398 studies 18, the usefulness of gene copy number analysis and the relationship 
between response and copy number needs to be clarified.  
 
Activation of FGFR1 signaling can lead to tumorigenesis by affecting a number of 
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downstream signaling. While signal transduction pathways initiating FGFR-
dependent oncogenesis differ depending on cellular context 42, our results 
demonstrated that the MAPK/ERK pathway is the major downstream pathway 
under control of FGFR1 in FGFR1-amplified lung cancer cell lines. In FGFR1-
amplified but low FGFR1 protein expressing lung cancers, other RTK’s have 
significant control of MEK/ERK signaling; co-inhibition with FGFR inhibitors, 
however, are required for marked suppression. This demonstrates that FGFR1-
amplified lung cancers with low FGFR1 protein expression require an additional, 
aberrantly active RTK to activate the MEK/ERK pathway, the co-existence of which 
may be necessary for transformation. Furthermore, requirement of co-inhibition to 
suppress FRS2 phosphorylation may suggest a crosstalk between FGFR1 and the co-
active RTK.   
 
Lastly, the addition of a PI3K inhibitor enhanced efficacy of FGFR inhibitor in the 
DMS-114 and NCI-H520 cell lines. In these FGFR1-amplified lung cancers with high 
FGFR1 protein and intermediate to high sensitivity to FGFR inhibitors, treatment 
with FGFR inhibitor led to downregulated MEK/ERK signaling but did not affect 
PI3K/AKT signaling. Effective treatments with TKIs in oncogene-addicted cancers 
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invariably lead to decreased signaling along the downstream PI3K/AKT and 
MEK/ERK pathways. Interestingly, the FGFR inhibitor PD173074 downregulates 
both AKT and ERK signaling in multiple FGFR2-amplified gastric cancer cell lines, 
resulting in cell death 43. Therefore, downstream signaling regulated by amplified 
FGFR may depend on which family member protein is altered.  
 
In conclusion, we have demonstrated that high FGFR1 protein expression is 
surprisingly absent in a significant number of FGFR1-amplified lung cancers, and 
these cancers are uniformly resistant to FGFR inhibitors. As such, the identification 
of co-existing driver RTKs are necessary to treat patients with FGFR1-amplified 
tumors with low protein expression. Notably, a master protocol study, Lung-MAP 
project is designed to screen samples by next-generation sequencing and planned to 
enroll patients in biomarker-driven phase II/III studies in SCC lung carcinoma 44.  
Here, we propose an alternative screening strategy for FGFR1-amplified lung SCCs 





Materials and Methods 
Cell lines and reagents 
 The lung cancer cell lines NCI-H1581, DMS-114, NCI-H520, NCI-H1703, Calu-3, 
and NCI-H2444 were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). HCC95 was obtained from the Korean Cell Line Research 
Foundation. MRC-5 was obtained from the Japanese Cell Research Bank. Colo-699N 
was obtained from the European Collection of Cell Cultures. Cells were cultured in 
RPMI1640 (Invitrogen, Carlsbad, CA, USA) with 5% FBS. All cell lines were tested 
and authenticated by short tandem repeat (STR) analysis with GenePrint 10 System 
(Promega, Milan, Italy) by the Japanese Cell Research Bank. Cells were regularly 
screened for Mycoplasma using a MycoAlert Mycoplasma Detection Kit (Lonza, 
Verviers, Belgium). NVP-BGJ398, AZD4547, PD173074, and imatinib were obtained 
from Active Biochem (Hong Kong, China). Lapatinib was purchased from Selleck 
(Houston, TX, USA). Compounds were dissolved in DMSO to a final concentration of 
10 mmol/l and stored at –20°C.  
 
Growth assay 
Assay was performed as previously described 45. Luminescence was recorded by 
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iMark Microplate Reader (Bio-Rad, Hercules, CA, USA). 
 
Gene copy number analysis 
Genomic DNA was extracted by DNeasy Blood & Tissue Kit (QIAGEN, Velno, 
Limburg, Netherlands). Gene copy number of FGFR1 was analyzed using TaqMan 
gene copy number assay (Assay ID: Hs01694937_cn, Applied Biosystems, Carlsbad, 
CA, USA), according to the manufacturer's instructions. TaqMan Copy Number 
Reference Assay, human RNase P was used as the endogenous reference gene. Fold 
increase in copy number was calculated as the ratio of the FGFR1 signal in each cell 
lines to that obtained in the normal FGFR1 gene expressing MRC-5 cells. 
 
Quantitative PCR analysis 
RNA was extracted using the RNeasy kit (QIAGEN), and cDNA was generated by 
the Omniscript Reverse Transcriptase kit (QIAGEN) according to the 
manufacturer's instructions. The amount of amplicon was determined with the 
Mx3005P qPCR System using TaqMan Universal PCR Master Mix (Applied 
Biosystems). Each sample was normalized to the housekeeping gene actin. All 
samples were analyzed in triplicate, and the relative expression to MRC-5 was 
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determined. Primer sets are FGFR1 forward (5’-TAATGGACTCTGTGGTGCCCTC-
3’) and FGFR1 reverse (5’-ATGTGTGGTTGATGCTGCCG-3’); β-actin forward (5’-




For Western blot analysis, lysates were prepared using Cell Lysis Buffer (Cell 
Signaling Technologies, Danvers, MA, USA); the procedure for Western blotting was 
as previously described 45. Antibodies used in this study are summarized in 
Supplementary Table 4. Human phospho-RTK arrays were obtained from R&D 
Systems (Minneapolis, MN, USA) and used according to the manufacturer’s 
instructions. The method to detect secreted NRG1 was previously described 27. All 
immunoblots are representative of three independent experiments and RTK array 
was replicated twice. 
 
siRNA knockdown 
Cells were seeded into 6-well plates at a density of 1-2 × 105 cells/well. Twenty-four 
hours later, cells were transfected with two siRNAs against FGFR1 (Dharmacon, 
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Lafayette, CO, USA) or Stealth RNAi-negative control low GC Duplex #3 
(Invitrogen) using Lipofectamine RNAiMAX (Invitrogen). Transfected cells were 
cultured at 37°C for 5 days before analysis. 
 
Lentiviral shRNA experiments 
shNRG1 constructs were obtained from Openbiosystems (Carlsbad, CA, USA) and 
control shRNA was from Addgene (Cambridge, MA, USA). The target sequences of 
NRG1 were CGTGGAATCAAACGAGATCAT for shNRG #1 and 
GCCTCAACTGAAGGAGCATAT for shNRG1 #2, respectively. Preparation of 
lentivirus and infections were performed as previously described 45. 
 
Fluorescence in situ hybridization (FISH) 
Bacterial artificial chromosome (BACPAC Resources, Oakland CA, USA) of RP11-
148D21 specific to the FGFR1 locus (8p11.23-11.22) was labeled with 
SpectrumOrangeTM using a nick translation kit (Abbott, Abbott Park IL, USA). 
Centromere 8 labeled with SpectrumGreenTM (CEP8TM, Abbott) was paired for copy 
number control. FISH was performed using standard methods and included a RNase 
A treatment 46. Only nuclei with unambiguous CEP8TM signals were scored for the 
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FGFR1 signal number. Two independent researchers (HK and KK) blindly scored 
thirty cells each to determine the gene copy number and the pattern of gene 
amplification. The results were concordant between two researchers in all cell lines. 
FGFR1 copy number relative to the chromosome 8 centromere copy number was 
calculated as the average of 60 cells. Gene amplification was defined as cells 
harboring FGFR1 copy number control ratio 2.0 or higher. The PathVysion HER-2 
DNA Probe Kit (PathVysion Kit, Abbott) was used to determine amplification of the 
HER-2/neu gene and assessed by LSI Medience Corporation Japan. Images were 
captured using a standard setting by Axio Imager 72 (Zeiss, Thornwood, NY, USA). 
 
Xenograft mouse studies  
For xenograft experiments, a suspension of 5 × 106 cells was injected subcutaneously 
into the flanks of 6- to 8-week-old male nude mice (Clea, Tokyo, Japan). The care and 
treatment of experimental animals were in accordance with institutional guidelines. 
The sample size was 12. Mice were randomized (n = 6 per group) once the mean 
tumor volume reached approximately 200 mm3, and there were no exclusion criteria. 
All data were analysed unblinded and verified by two independent researchers (HK 
and HE). NVP-BGJ398 was dissolved in acetic acid/acetate buffer pH 4.6/PEG300 
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1:1. Tumors were measured twice weekly using calipers, and volume was calculated 
using the following formula: length × width2 × 0.52. Mice were monitored daily for 
body weight and general condition. Xenograft experiments were approved by the 
ethical committee on the Institute for Experimental Animals, Kanazawa University 
Advanced Science Research Center.  
 
Immunohistochemistry (IHC) 
 Immunohistochemistry was performed on TMA sections using rabbit polyclonal 
antibody to FGFR1 (abcam, Cambridge, MA, USA, ab137781, 1:50). Staining was 
performed using the Leica RX Bond Autostainer (Leica Biosystems, IL, USA). 
Antigen retrieval was performed in ER 1 (Citrate buffer) for 20 min and stained 
using the Bond Polymer Refine Protocol under the IHC Modified F Protocol as 
previously described 47. Positive control included xenografted tumor samples of NCI-
H1581. Each TMA tumor core was assessed by a pathologist (MMK) semi-
quantitatively based on the extent of tumor cells with membranous staining and the 
intensity of membranous staining as follows: 0, no staining; 1+, any staining in <50% 
of tumor cells or only faint/weak staining in >50% of tumor cells; 2+, moderate/strong 
staining in >50% of tumor cells. Multiples cores from each patient were collectively 
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assessed. Cases with 1+ and 2+ staining were regarded as positive. FISH analysis of 
FGFR1 and PDGFRα in these samples was previously described 10. This study was 
approved by The Institutional Review Board at Massachusetts General Hospital. 
Informed consent was obtained from all patients. 
 
Analysis of publicly available dataset 
Information regarding FGFR1, HER2, and PDGFRα amplification and FGFR1 and 
NRG1 expression data of primary lung SCCs were from The Cancer Genome Atlas 
(TCGA) repository and obtained through the cBioPortal 16, 48, 49. FGFR1 and NRG1 




Statistical tests were performed by linear regression analysis and Fisher’s exact test 
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Figure 1. Protein expression is associated with sensitivity to FGFR inhibitor in 
FGFR1 amplified lung cancer cell lines. 
 
(a) FGFR1 gene copy number was analyzed by Taqman gene copy number assay. 
Fold increase in copy number was calculated as the ratio of the FGFR1 signal in 
each cell lines to that of obtained in human fetal lung fibroblast MRC-5 cells. 
Error bars represent SD of triplicate independent experiments. 
(b) Copy number of FGFR1 measured by FISH. Centromere 8 was co-stained and 
the ratio of FGFR1 to CEP8 is shown.  
(c, d, e) Six FGFR1 amplified cell lines were treated with three pan-FGFR inhibitors, 
NVP-BGJ398 (c), AZD4547 (d), and PD-173074 (e). Error bars represent mean + SD. 
(f) mRNA level of FGFR1 was analyzed by quantitative PCR. Fold increase in 
mRNA to MRC-5 cells was shown. Error bars represent SD of triplicate 
independent experiments. 
(g) The levels of FGFR1 protein expression were shown. Immunoblots in Figure 3a 





Figure 2. FGFR1 protein expressing, but FGFR1 non-amplified cells are insensitive 
to pan-FGFR inhibitors. 
 
(a) IC50 data to PD-173074 was obtained from The Genomics of Drug Sensitivity in 
Cancer Project (http://www.cancerrxgene.org/). FGFR1 mRNA expression data was 
obtained from Cancer Cell Line Encyclopedia 
(http://www.broadinstitute.org/ccle/home).  Each cells were plotted by FGFR1 
mRNA (x axis) and IC50 to PD-173074 (Y axis). Sensitive cells (NCI-H1581 and 
DMS-114) were denoted in red. 
 
(b) Expression of FGFR1 mRNA is not enough to be sensitive to FGFR inhibitor. The 
relationship between gene amplification and sensitivity to FGFR inhibitor among 
FGFR1 mRNA expressed cells were determined by fisher’s exact test. FGFR1 
expression was defined as high when mRNA level was higher than median. 
 
(c) Non-FGFR1 amplified Colo-699N cells have comparable FGFR1 protein 
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expression to FGFR1 amplified NCI-H1581 cells. Cells were lysed and blotted by 
indicated antibodies. 
(d) NCI-H1581 and Colo-699N cells were treated with NVP-BGJ398. Error bars 
represent mean + SD. 
(e, f) Xenograft tumors derived from the NCI-H1581 (e) or Colo-699N (f) cells were 
developed. Once they achieved an average size of 200 mm3, the tumors were treated 
with 25 mg/kg of NVP-BGJ398 by oral gavage once daily, and tumor volumes were 
plotted over time (mean ± SEM). 
 
Figure 3. FGFR1 regulates ERK signaling in both FGFR1 amplified and protein 
expressing cells. 
 
(a) Cells were lysed and blotted with indicated antibodies. Independent experiments 
were performed three times, and a representative result is shown. 
(b) Cells were treated with 1µM NVP-BGJ398 for 24h and cell lysates were blotted 
with indicated antibodies 
(c) The indicated cell lines were transfected with siRNA against FGFR1 or control 
siRNA (siCtr). Cells were lysed 5 days after transfection. 
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(d) NCI-H520 cells were treated with indicated dose of NVP-BGJ398 for 6 hrs. Cell 
lysates were blotted with phosphorylated and total ERK protein. 
(e) The levels of p-ERK were quantified in (D) and are presented as percentage of 
phosphorylated ERK relative to DMSO treated cells.  
(f) Cells were treated with indicated concentration of NVP-BGJ398 for 72 hrs and 
cell proliferation was shown. Error bars represent mean + SD. 
(g) Cells were treated with 1µM GDC-0941, 1µM NVP-BGJ398, and combination of 
these two drugs for 24hrs. Then cells were lysed and blotted with indicated 
antibodies. 
(h)  The number of viable cells was determined by Cell Counting Kit and presented 
as percentage change of cells compared with day 0 (i.e., negative values indicate 
loss of cells from day 0). Error bars are SD of cells treated n=6. 
 
Figure 4. Co-existing driver mutations in low protein expressing FGFR1 amplified 
cell lines. 
(a, b) Cells were treated with DMSO or 1µM NVP-BGJ398 for 24h, and cell lysates 
were assessed for levels of phosphorylated RTKs using phospho-RTK arrays. 
Internal controls at the corner of each membrane allow comparison of phospho-RTK 
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levels between arrays. Upregulated RTKs are indicated. 
 
Figure 5. Elevated NRG1 expression mitigates the effect of FGFR inhibitor in 
HCC95 cells 
 
(a) Cells were treated with DMSO or 1µM NVP-BGJ398 for 24h, and cell lysates 
were assessed for levels of phosphorylated RTKs using phospho-RTK arrays. 
Internal controls at the corner of each membrane allow comparison of phospho-
RTK levels between arrays. Upregulated RTKs are indicated. 
(b) HCC95 cells do not have HER2 amplification. Representative HER2/CEP17 
signal pattern is shown. HER2/CEP17 ratio was 0.94. 
(c, d) NRG1 is overexpressed in HCC95 cells. (C) mRNA level of NGR1 was 
determined by quantitative PCR. Fold increase in RNA level was calculated as the 
ratio of the NRG1 in each cell lines to that of obtained in human fetal lung fibroblast 
MRC-5 cells. (d) Cells were lysed and blotted with each antibody. 
(e, f) Cells were infected with either scramble shRNA vector or two NRG1 shRNA 
vectors. (e) Cells were lysed after 5 days following shRNA infection and blotted 
with NRG1 antibody in HCC95 cells. NCI-H520 cells do not express NRG1 and 
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were used as a negative control. (f) Cell viability was determined by Cell 
Counting Kit. Error bars are SD of cells treated n=6. 
(g) HER3 activation in NCI-H1581 cells following the addition of conditioned 
medium from HCC95 cells. Cells were added conditioned media and lysted after 
60 min. 
 
Figure 6. Inhibition of FGFR with co-existing driver protein enhanced growth 
suppression and apoptosis induction in FGFR1 amplified cells with low protein 
expression. 
 
(a) While NCI-H1703 cells were treated with 1µM NVP-BGJ398, 1µM imatinib, or 
combination of these two drugs, Calu-3 and HCC95 cells were treated with 1µM 
NVP-BGJ398, 1µM lapatinib, or combination of these two drugs. Drug containing 
media was replaced at 72 hr treatment. Following five day treatment, plates were 
stained with crystal violet. A representative plates are shown. 
(b) Cells were treated with 1µM of each drug and drug combinations for 24 hrs. Cells 





Figure 7. Tumors harboring both FGFR1 gene amplification and protein expression 
are only a small fraction of FGFR1 amplified lung SCC and do not have other driver 
oncogenes.  
 
(a) Results of FGFR1 IHC staining of FGFR1 gene amplified SCC carcinoma. Gene 
amplification was defined by FISH analysis. 
(b) TCGA data set for RNAseq of 178 lung SCCs were queried for FGFR1 
amplification, PDGFRα amplification, FGFR1 mRNA expression and NRG1 mRNA 
expression. FGFR1 and NRG1 expression was defined as positive when the Z-score 
of mRNA level was higher than 2. 
(c) Proposed treatment strategies for the treatment of FGFR1 amplified lung SCCs. 
 
Supplementary figure legend 
 
Supplementary Figure S1. FGFR1 gene is not amplified in NCI-H2444. 
Left) FGFR1 gene copy number was analyzed by Taqman gene copy number assay. 
Fold increase in copy number was calculated as the ratio of the FGFR1 signal to 
that of obtained in human fetal lung fibroblast MRC-5 cells.  
Right) Copy number of FGFR1 measured by FISH. Centromere 8 was co-stained 
and the ratio of FGFR1 to CEP8 is shown.  
 
Supplementary Figure S2. Protein expression is associated with sensitivity to 
FGFR inhibitor in FGFR1 amplified cell line. 
(a, b, c) The relationships between FGFR1 protein expression and FISH (a), gene 
copy number (b), and mRNA (c) are shown. 
(d) Cells were categorized based on protein expression and sensitivity to 
NVP-BGJ398. 
 
Supplementary Figure S3. Absence of CpG island methylation in promoter region of 
FGFR1. 
Genomic DNA was extracted by DNeasy Blood and Tissue Kit (QIAGEN) and 
prepared for methylation analysis with EpiTect Methyl DNA Restriction Kit 
(QIAGEN). Methylation status of a CpG island in the FGFR1 promoter was 
detected using EpiTect Methyl DNA Methylation qPCR Primer Assays from 
QIAGEN and calculated according to the manufacturer's instruction. Genomic DNA 
purified from HCT116 cell line genetically lacking methyltransferases 
(HCT-116-UM) were used as a negative control. In addition, HCT-116 genomic DNA 
highly methylated by CpG methylase (HCT-116-M) was used as positive control. 
Both sets of genomic DNA were obtained from Takara Bio Japan. 
 
Supplementary Figure S4. Colo-699N is non-FGFR1 gene amplified cells. 
Left) FGFR1 gene copy number of Colo-699N cells was analyzed by Taqman gene 
copy number assay. Fold increase in copy number was calculated as the ratio of the 
FGFR1 signal to that of obtained in human fetal lung fibroblast MRC-5 cells.  
Right) Copy number of FGFR1 (2.7) and centromere 8 (2.1) were determined by 
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